168 results on '"Bernardo, Bianca C."'
Search Results
2. Estrogen receptor alpha deficiency in cardiomyocytes reprograms the heart-derived extracellular vesicle proteome and induces obesity in female mice
3. Translational Potential of Non-coding RNAs for Cardiovascular Disease
4. A gene therapy targeting medium-chain acyl-CoA dehydrogenase (MCAD) did not protect against diabetes-induced cardiac pathology
5. The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection
6. Adeno-Associated Virus Gene Therapy: Translational Progress and Future Prospects in the Treatment of Heart Failure
7. Molecular Aspects of Exercise-induced Cardiac Remodeling
8. From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure
9. In Vivo Inhibition of miR-34a Modestly Limits Cardiac Enlargement and Fibrosis in a Mouse Model with Established Type 1 Diabetes-Induced Cardiomyopathy, but Does Not Improve Diastolic Function
10. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets
11. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function
12. A MicroRNA Guide for Clinicians and Basic Scientists: Background and Experimental Techniques
13. The yin and yang of adaptive and maladaptive processes in heart failure
14. Inhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure Overload
15. MicroRNAs differentially regulated in cardiac and skeletal muscle in health and disease: Potential drug targets?
16. Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways
17. The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy
18. FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K
19. Old Drug, New Trick: Tilorone, a Broad-Spectrum Antiviral Drug as a Potential Anti-Fibrotic Therapeutic for the Diseased Heart
20. Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies
21. Non-coding RNAs regulating cardiac muscle mass
22. Noncoding RNAs regulating cardiac muscle mass
23. βAdrenergic stimulation induces histone deacetylase 5 (HDAC5) nuclear accumulation in cardiomyocytes by B55α-PP2A-mediated dephosphorylation
24. β‐Adrenergic Stimulation Induces Histone Deacetylase 5 (HDAC5) Nuclear Accumulation in Cardiomyocytes by B55α‐PP2A‐Mediated Dephosphorylation
25. Generation of MicroRNA-34 Sponges and Tough Decoys for the Heart: Developments and Challenges
26. Lipidomic Profiles of the Heart and Circulation in Response to Exercise versus Cardiac Pathology: A Resource of Potential Biomarkers and Drug Targets
27. Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling
28. Understanding Key Mechanisms of Exercise-Induced Cardiac Protection to Mitigate Disease: Current Knowledge and Emerging Concepts
29. Inhibition of miR-29 protects against cardiac hypertrophy and fibrosis: new insight for the role of miR-29 in the heart
30. Abstract 394: Medium Chain Acyl-Coenzyme a Dehydrogenase Gene Therapy Induces Physiological Cardiac Hypertrophy and Protects Against Pathological Remodeling
31. HSP70: therapeutic potential in acute and chronic cardiac disease settings
32. Therapeutic potential of targeting microRNAs to regulate cardiac fibrosis: miR-433 a new fibrotic player
33. Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice
34. Sex differences in response to miRNA‐34a therapy in mouse models of cardiac disease: identification of sex‐, disease‐ and treatment‐regulated miRNAs
35. Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: Implications for treating cardiac pathology and other diseases
36. Long-Term Overexpression of Hsp70 Does Not Protect against Cardiac Dysfunction and Adverse Remodeling in a MURC Transgenic Mouse Model with Chronic Heart Failure and Atrial Fibrillation
37. miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart
38. The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice
39. Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: Implications for treating cardiac pathology and other diseases.
40. Therapeutic silencing of miR‐652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy
41. Abstract 58: Identification Of miRNA-34 Networks In Pathological Cardiac Remodeling
42. Abstract 50: Therapeutic Silencing of miRNA-652 Restores Cardiac Function and Attenuates Pathological Remodeling in a Mouse Model of Pressure Overload
43. O166 Inhibition of miRNA-652 Using LNA-antimiRs Improves Cardiac Function in a Mouse Model of Pressure Overload and is Associated with Preserved Angiogenesis and Upregulation of Jagged 1
44. PT353 Identification of miRNA networks in pathological cardiac remodelling-New therapeutic targets
45. Silencing of miR-34a Attenuates Cardiac Dysfunction in a Setting of Moderate, but Not Severe, Hypertrophic Cardiomyopathy
46. The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass
47. The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass
48. The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass
49. Phosphoinositide 3-Kinase p110α Is a Master Regulator of Exercise-Induced Cardioprotection and PI3K Gene Therapy Rescues Cardiac Dysfunction
50. Changes in the Chondrocyte and Extracellular Matrix Proteome during Post-natal Mouse Cartilage Development
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.